Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes

Articles with lock require a subscription to GLG News | Request a free trial
Carlos DujovneJanuary 17, 2008
Merck Developement of Anacetrapib not as Risky as it may appear!
Analysis of: Merck & Co.: Engaging in Risky Business? | www.pharmaweek.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
My expertise in the clinical research of Torcetrapib and reports presented at the latest American College of Cardiology meetings made me conclude that the failure of  Torcetrapib in rendering clinical benefits were related to intrinsic problems of the drug which effected the nature of the HDL which...
Carlos DujovneJanuary 17, 2008
Merck Developement of Taranabant not as Risky as it may appear!
Analysis of: Merck & Co.: Engaging in Risky Business? | www.pharmaweek.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Those like myself who have more extensive knowledge on the rational used by the FDA to reject the approval of Rimonabant and know the differences between Rimonabant and Taranabant do not believe that there is an error in judgment by Merck in developing their new cannabinoid receptor antagonist. This...
January 14, 2008
Major Boon for Diabetes Companies, if only...
Analysis of: Diabetes legislation proposed | www.bizjournals.com
Author: GLG Expert Contributor
Diabesity is pandemic, too late diagnosed, too little treated.  ADA recommendations for screening with fasting blood sugars result in relatively late diagnoses since the FBS doesn't usually rise until the disease has been present for several years. 
Joseph BassJanuary 9, 2008
Alogliptin on the diabetes horizon.
Analysis of: Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare
Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.
December 7, 2007
the truth about avandia and osteoporosis
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Expert Contributor
-the relationship between avandia and ostoeporosis -implcations in clinical practice -implications for the future of avandia
Carlos DujovneNovember 26, 2007
Liraglutide benefis in obesity not as greater as authors claim when compared to Orlistat
Analysis of: New Phase 2 Study Shows That Liraglutide Leads to Significant Weight Loss in Obese People | pharmalive.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
As past Principal Investigator in most clinical trials wit Orlistat I can offer a different interpretations of tthe resuls of the comparayive study just announced,as follows.1.The result on diabetes or glucose regulation were earlier with Liraglutide,possibly because it has specific antidiabetic(besides...
October 11, 2007
Bogus
Analysis of: Burden of diabetes care rivals disease complications | www.reuters.com
Author: GLG Expert Contributor
No implications, except how these patients are receiving intensive insulin therapy may need to be improved.
October 4, 2007
Rimonabandt ( Accomplia) a viable and an effective tool in managenent of obesity
Analysis of: Sanofi aims to show there's still life in Acomplia | www.reuters.com
Author: GLG Expert Contributor
Accomplia would be an effective new tool in management of obesity'A Dormant Volcano Waiting to Erupt' even amongst our youngsters,.Granted that it has adverseeffects i.e depression, suicidal ieation etc. However these disorders are frequently noted in Obese patients not using any meds it is also clear...
October 3, 2007
Galvus Approved in Europe
Analysis of: Galvus(R) receives European approval as new treatment for type 2 diabetes with broad range of indications | www.pipelinereview.com
Author: GLG Expert Contributor
Galvus is now approved for use in all 27 countries of the European Union, plus Norway, Iceland, Brazil, and Mexico.  It is the first in it's class to be approved for combination therapy with all three of the most commonly prescribed oral diabetic agents--metformin, sulfonyureas,...
September 26, 2007
Another "cure" for diabetes?
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Expert Contributor
1. Weight loss may improve carbohydrate metabolism in patients with  Type 2 DM 2. Weight loss is difficult to maintain even in these patients 3. There is more to curing type 2 DM then losing weight

Previous Page : 1 2 3 4 5 6 7 8 9 10 Next31 to 40 of 93

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773